Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis

Background and Objectives: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderl...

Full description

Saved in:
Bibliographic Details
Published in:Medicina (Kaunas, Lithuania) Lithuania), 2021-08, Vol.57 (9), p.914
Main Authors: Sato, Shuzo, Matsumoto, Haruki, Temmoku, Jumpei, Fujita, Yuya, Matsuoka, Naoki, Yashiro-Furuya, Makiko, Asano, Tomoyuki, Suzuki, Eiji, Watanabe, Hiroshi, Kanno, Takashi, Migita, Kiyoshi
Format: Article
Language:English
Subjects:
abatacept
Biological products
Clinical medicine
DMARD
elderly
Infections
Medical prognosis
Patients
Remission (Medicine)
Retention
Rheumatoid arthritis
tacrolimus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c467t-b8979d61ec3a7618242bf22d25d3ecb7446430c6863861c816b3efe26374fb4f3
cites cdi_FETCH-LOGICAL-c467t-b8979d61ec3a7618242bf22d25d3ecb7446430c6863861c816b3efe26374fb4f3
container_end_page
container_issue 9
container_start_page 914
container_title Medicina (Kaunas, Lithuania)
container_volume 57
creator Sato, Shuzo
Matsumoto, Haruki
Temmoku, Jumpei
Fujita, Yuya
Matsuoka, Naoki
Yashiro-Furuya, Makiko
Asano, Tomoyuki
Suzuki, Eiji
Watanabe, Hiroshi
Kanno, Takashi
Migita, Kiyoshi
description Background and Objectives: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderly RA patients; however, the real-world data of efficacy and long-term retention of ABT is sparse in such patients. This study aimed to investigate the clinical efficacy and long-term retention rates of ABT in elderly Japanese RA patients. Materials and Methods: This 10-year retrospective observational cohort study was performed in two centers in Fukushima, Japan. We reviewed the clinical features of elderly RA patients who received ABT and investigated the differences in retention rates with concomitant administration of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Results: The clinical characteristics of younger (
doi_str_mv 10.3390/medicina57090914
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_19504c2865804f2b8596b07582a8d917</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_19504c2865804f2b8596b07582a8d917</doaj_id><sourcerecordid>2576442175</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-b8979d61ec3a7618242bf22d25d3ecb7446430c6863861c816b3efe26374fb4f3</originalsourceid><addsrcrecordid>eNpdkk1v1DAQQCMEoqVw52iJC5eAv2I7F6TVtkClRaBtOUeOM8l6ldiL7RTtr-Iv4m4qRHvyaOb52aOZonhL8AfGavxxgs4a63QlcY1rwp8V50RwVeaQP_8vPitexbjHmNFK0pfFGeOVlIrJ8-LPzRyTtg46tPFuKG8hTGgLCVyy3qGtThCR79Gq1UkbOCRkHVr7qc2vnojfNu1ywt0tN_SIbo4u7SBZgy5tBB2h_OY72x-tG9AqQ2EH86RP9TAP8V54NXYQxiP6kdPZExfrdgG97dAqpF2wycbXxYtejxHePJwXxc_PV7frr-Xm-5fr9WpTGi5kKltVy7oTBAzTUhBFOW17SjtadQxMKzkXnGEjlGBKEKOIaBn0QAWTvG95zy6K68Xbeb1vDsFOOhwbr21zSvgwNDrkHkZoSF1hbqgSlcK8p62qatFiWSmqVVcTmV2fFtdhbvPETO4w6PGR9HHF2V0z-LtGcVFjXGfB-wdB8L9miKmZbDQwjtqBn2OTpyp5pSTDGX33BN37OeSxnCjBOSWyyhReKBN8jAH6f58huLnfrObpZrG_Ep7EoA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2576442175</pqid></control><display><type>article</type><title>Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Sato, Shuzo ; Matsumoto, Haruki ; Temmoku, Jumpei ; Fujita, Yuya ; Matsuoka, Naoki ; Yashiro-Furuya, Makiko ; Asano, Tomoyuki ; Suzuki, Eiji ; Watanabe, Hiroshi ; Kanno, Takashi ; Migita, Kiyoshi</creator><creatorcontrib>Sato, Shuzo ; Matsumoto, Haruki ; Temmoku, Jumpei ; Fujita, Yuya ; Matsuoka, Naoki ; Yashiro-Furuya, Makiko ; Asano, Tomoyuki ; Suzuki, Eiji ; Watanabe, Hiroshi ; Kanno, Takashi ; Migita, Kiyoshi</creatorcontrib><description>Background and Objectives: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderly RA patients; however, the real-world data of efficacy and long-term retention of ABT is sparse in such patients. This study aimed to investigate the clinical efficacy and long-term retention rates of ABT in elderly Japanese RA patients. Materials and Methods: This 10-year retrospective observational cohort study was performed in two centers in Fukushima, Japan. We reviewed the clinical features of elderly RA patients who received ABT and investigated the differences in retention rates with concomitant administration of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Results: The clinical characteristics of younger (&lt;75 years old, 39 cases) and elderly (≥75 years old, 20 cases) RA patients were generally similar. Although the efficacy was also similar, the concomitant administration of csDMARDs with ABT differed between the two groups. Younger patients significantly decreased methotrexate (MTX) administration than elderly patients (p &lt; 0.01), and elderly patients significantly received tacrolimus (TAC) (p &lt; 0.01) or salazosulfapyridine (SASP; p = 0.01) than younger patients. The overall retention and infection-free survival rates were similar between the two groups. Conclusion: Elderly RA patients showed sustained retention rates compared to younger RA patients. TAC and SASP can help to maintain sustained retention rates in elderly RA patients.</description><identifier>ISSN: 1648-9144</identifier><identifier>ISSN: 1010-660X</identifier><identifier>EISSN: 1648-9144</identifier><identifier>DOI: 10.3390/medicina57090914</identifier><identifier>PMID: 34577837</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>abatacept ; Biological products ; Clinical medicine ; DMARD ; elderly ; Infections ; Medical prognosis ; Patients ; Remission (Medicine) ; Retention ; Rheumatoid arthritis ; tacrolimus</subject><ispartof>Medicina (Kaunas, Lithuania), 2021-08, Vol.57 (9), p.914</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-b8979d61ec3a7618242bf22d25d3ecb7446430c6863861c816b3efe26374fb4f3</citedby><cites>FETCH-LOGICAL-c467t-b8979d61ec3a7618242bf22d25d3ecb7446430c6863861c816b3efe26374fb4f3</cites><orcidid>0000-0002-8110-8261</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2576442175/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2576442175?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Sato, Shuzo</creatorcontrib><creatorcontrib>Matsumoto, Haruki</creatorcontrib><creatorcontrib>Temmoku, Jumpei</creatorcontrib><creatorcontrib>Fujita, Yuya</creatorcontrib><creatorcontrib>Matsuoka, Naoki</creatorcontrib><creatorcontrib>Yashiro-Furuya, Makiko</creatorcontrib><creatorcontrib>Asano, Tomoyuki</creatorcontrib><creatorcontrib>Suzuki, Eiji</creatorcontrib><creatorcontrib>Watanabe, Hiroshi</creatorcontrib><creatorcontrib>Kanno, Takashi</creatorcontrib><creatorcontrib>Migita, Kiyoshi</creatorcontrib><title>Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis</title><title>Medicina (Kaunas, Lithuania)</title><description>Background and Objectives: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderly RA patients; however, the real-world data of efficacy and long-term retention of ABT is sparse in such patients. This study aimed to investigate the clinical efficacy and long-term retention rates of ABT in elderly Japanese RA patients. Materials and Methods: This 10-year retrospective observational cohort study was performed in two centers in Fukushima, Japan. We reviewed the clinical features of elderly RA patients who received ABT and investigated the differences in retention rates with concomitant administration of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Results: The clinical characteristics of younger (&lt;75 years old, 39 cases) and elderly (≥75 years old, 20 cases) RA patients were generally similar. Although the efficacy was also similar, the concomitant administration of csDMARDs with ABT differed between the two groups. Younger patients significantly decreased methotrexate (MTX) administration than elderly patients (p &lt; 0.01), and elderly patients significantly received tacrolimus (TAC) (p &lt; 0.01) or salazosulfapyridine (SASP; p = 0.01) than younger patients. The overall retention and infection-free survival rates were similar between the two groups. Conclusion: Elderly RA patients showed sustained retention rates compared to younger RA patients. TAC and SASP can help to maintain sustained retention rates in elderly RA patients.</description><subject>abatacept</subject><subject>Biological products</subject><subject>Clinical medicine</subject><subject>DMARD</subject><subject>elderly</subject><subject>Infections</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Remission (Medicine)</subject><subject>Retention</subject><subject>Rheumatoid arthritis</subject><subject>tacrolimus</subject><issn>1648-9144</issn><issn>1010-660X</issn><issn>1648-9144</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1v1DAQQCMEoqVw52iJC5eAv2I7F6TVtkClRaBtOUeOM8l6ldiL7RTtr-Iv4m4qRHvyaOb52aOZonhL8AfGavxxgs4a63QlcY1rwp8V50RwVeaQP_8vPitexbjHmNFK0pfFGeOVlIrJ8-LPzRyTtg46tPFuKG8hTGgLCVyy3qGtThCR79Gq1UkbOCRkHVr7qc2vnojfNu1ywt0tN_SIbo4u7SBZgy5tBB2h_OY72x-tG9AqQ2EH86RP9TAP8V54NXYQxiP6kdPZExfrdgG97dAqpF2wycbXxYtejxHePJwXxc_PV7frr-Xm-5fr9WpTGi5kKltVy7oTBAzTUhBFOW17SjtadQxMKzkXnGEjlGBKEKOIaBn0QAWTvG95zy6K68Xbeb1vDsFOOhwbr21zSvgwNDrkHkZoSF1hbqgSlcK8p62qatFiWSmqVVcTmV2fFtdhbvPETO4w6PGR9HHF2V0z-LtGcVFjXGfB-wdB8L9miKmZbDQwjtqBn2OTpyp5pSTDGX33BN37OeSxnCjBOSWyyhReKBN8jAH6f58huLnfrObpZrG_Ep7EoA</recordid><startdate>20210831</startdate><enddate>20210831</enddate><creator>Sato, Shuzo</creator><creator>Matsumoto, Haruki</creator><creator>Temmoku, Jumpei</creator><creator>Fujita, Yuya</creator><creator>Matsuoka, Naoki</creator><creator>Yashiro-Furuya, Makiko</creator><creator>Asano, Tomoyuki</creator><creator>Suzuki, Eiji</creator><creator>Watanabe, Hiroshi</creator><creator>Kanno, Takashi</creator><creator>Migita, Kiyoshi</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8110-8261</orcidid></search><sort><creationdate>20210831</creationdate><title>Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis</title><author>Sato, Shuzo ; Matsumoto, Haruki ; Temmoku, Jumpei ; Fujita, Yuya ; Matsuoka, Naoki ; Yashiro-Furuya, Makiko ; Asano, Tomoyuki ; Suzuki, Eiji ; Watanabe, Hiroshi ; Kanno, Takashi ; Migita, Kiyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-b8979d61ec3a7618242bf22d25d3ecb7446430c6863861c816b3efe26374fb4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>abatacept</topic><topic>Biological products</topic><topic>Clinical medicine</topic><topic>DMARD</topic><topic>elderly</topic><topic>Infections</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Remission (Medicine)</topic><topic>Retention</topic><topic>Rheumatoid arthritis</topic><topic>tacrolimus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sato, Shuzo</creatorcontrib><creatorcontrib>Matsumoto, Haruki</creatorcontrib><creatorcontrib>Temmoku, Jumpei</creatorcontrib><creatorcontrib>Fujita, Yuya</creatorcontrib><creatorcontrib>Matsuoka, Naoki</creatorcontrib><creatorcontrib>Yashiro-Furuya, Makiko</creatorcontrib><creatorcontrib>Asano, Tomoyuki</creatorcontrib><creatorcontrib>Suzuki, Eiji</creatorcontrib><creatorcontrib>Watanabe, Hiroshi</creatorcontrib><creatorcontrib>Kanno, Takashi</creatorcontrib><creatorcontrib>Migita, Kiyoshi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Medicina (Kaunas, Lithuania)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sato, Shuzo</au><au>Matsumoto, Haruki</au><au>Temmoku, Jumpei</au><au>Fujita, Yuya</au><au>Matsuoka, Naoki</au><au>Yashiro-Furuya, Makiko</au><au>Asano, Tomoyuki</au><au>Suzuki, Eiji</au><au>Watanabe, Hiroshi</au><au>Kanno, Takashi</au><au>Migita, Kiyoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis</atitle><jtitle>Medicina (Kaunas, Lithuania)</jtitle><date>2021-08-31</date><risdate>2021</risdate><volume>57</volume><issue>9</issue><spage>914</spage><pages>914-</pages><issn>1648-9144</issn><issn>1010-660X</issn><eissn>1648-9144</eissn><abstract>Background and Objectives: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderly RA patients; however, the real-world data of efficacy and long-term retention of ABT is sparse in such patients. This study aimed to investigate the clinical efficacy and long-term retention rates of ABT in elderly Japanese RA patients. Materials and Methods: This 10-year retrospective observational cohort study was performed in two centers in Fukushima, Japan. We reviewed the clinical features of elderly RA patients who received ABT and investigated the differences in retention rates with concomitant administration of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Results: The clinical characteristics of younger (&lt;75 years old, 39 cases) and elderly (≥75 years old, 20 cases) RA patients were generally similar. Although the efficacy was also similar, the concomitant administration of csDMARDs with ABT differed between the two groups. Younger patients significantly decreased methotrexate (MTX) administration than elderly patients (p &lt; 0.01), and elderly patients significantly received tacrolimus (TAC) (p &lt; 0.01) or salazosulfapyridine (SASP; p = 0.01) than younger patients. The overall retention and infection-free survival rates were similar between the two groups. Conclusion: Elderly RA patients showed sustained retention rates compared to younger RA patients. TAC and SASP can help to maintain sustained retention rates in elderly RA patients.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34577837</pmid><doi>10.3390/medicina57090914</doi><orcidid>https://orcid.org/0000-0002-8110-8261</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1648-9144
ispartof Medicina (Kaunas, Lithuania), 2021-08, Vol.57 (9), p.914
issn 1648-9144
1010-660X
1648-9144
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_19504c2865804f2b8596b07582a8d917
source Open Access: PubMed Central; Publicly Available Content Database
subjects abatacept
Biological products
Clinical medicine
DMARD
elderly
Infections
Medical prognosis
Patients
Remission (Medicine)
Retention
Rheumatoid arthritis
tacrolimus
title Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A27%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20Long-Term%20Retention%20Rates%20of%20Abatacept%20in%20Combination%20with%20Conventional%20Synthetic%20Disease-Modifying%20Antirheumatic%20Drugs%20in%20Elderly%20Patients%20with%20Rheumatoid%20Arthritis&rft.jtitle=Medicina%20(Kaunas,%20Lithuania)&rft.au=Sato,%20Shuzo&rft.date=2021-08-31&rft.volume=57&rft.issue=9&rft.spage=914&rft.pages=914-&rft.issn=1648-9144&rft.eissn=1648-9144&rft_id=info:doi/10.3390/medicina57090914&rft_dat=%3Cproquest_doaj_%3E2576442175%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c467t-b8979d61ec3a7618242bf22d25d3ecb7446430c6863861c816b3efe26374fb4f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2576442175&rft_id=info:pmid/34577837&rfr_iscdi=true